Perspectives on Hypoxia Signaling in Tumor Stroma
Open accessThe DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Abstract
Hypoxia is a well-known characteristic of solid tumors that contributes to tumor progression and metastasis. Oxygen deprivation due to high demand of proliferating cancer cells and standard of care therapies induce hypoxia. Hypoxia signaling, mainly mediated by the hypoxia-inducible transcription factor (HIF) family, results in tumor cell migration, proliferation, metabolic changes, and resistance to therapy. Additionally, the hypoxic tumor microenvironment impacts multiple cellular and non-cellular compartments in the tumor stroma, including disordered tumor vasculature, homeostasis of ECM. Hypoxia also has a multifaceted and often contradictory influence on immune cell function, which contributes to an immunosuppressive environment. Here, we review the important function of HIF in tumor stromal components and summarize current clinical trials targeting hypoxia. We provide an overview of hypoxia signaling in tumor stroma that might help address some of the challenges associated with hypoxia-targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, hypoxia promotes self-renewal by activation of Wnt and Notch signaling pathways and embryonic stem cell transcription factors, and it modulates differentiation of tumor cells and tumor-associated stromal cells [86,87,88].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [88]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Gilkes, D. M., Bajpai, S., Chaturvedi, P., Wirtz, D., & Semenza, G. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442939 · Cited by 467
RetractedProcollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis
Gilkes, D. M., Bajpai, S., Wong, C. C., Chaturvedi, P., Hubbi, M. E., Wirtz, D., & Semenza, G. L. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0629 · Cited by 252
RetractedMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
The extracellular matrix at a glance
Frantz, C., Stewart, K. M., & Weaver, V. M. (2010) · Journal of Cell Science · doi:10.1242/jcs.023820 · Cited by 4,334
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R., & Chi, H. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110278 · Cited by 1,803
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Hypoxia signalling in cancer and approaches to enforce tumour regression
Pouysségur, J., Dayan, F., & Mazure, N. M. (2006) · Nature · doi:10.1038/nature04871 · Cited by 1,676
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
Dang, E. V., Barbi, J., Yang, H.-Y., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z., Fu, J., Kim, Y., Yen, H.-R., et al. (2011) · Cell · doi:10.1016/j.cell.2011.07.033 · Cited by 1,595
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
The impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?
Lutz, M. B., & Schuler, G. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02281-0 · Cited by 1,349
Bouchon, A., Dietrich, J., & Colonna, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.4991 · Cited by 1,284
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232
Erler, J. T., Bennewith, K. L., Cox, T. R., Lang, G., Bird, D., Koong, A., Le, Q.-T., & Giaccia, A. J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.11.012 · Cited by 1,231
HIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195
Hypoxia-Induced Angiogenesis: Good and Evil
Krock, B. L., Skuli, N., & Simon, M. C. (2011) · Genes & Cancer · doi:10.1177/1947601911423654 · Cited by 1,180
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
Du, R., Lu, K. V., Petritsch, C., Liu, P., Ganss, R., Passegué, E., Song, H., VandenBerg, S., Johnson, R. S., Werb, Z., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.034 · Cited by 1,130
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
Mechanisms and functional significance of tumour-induced dendritic-cell defects
Gabrilovich, D. (2004) · Nature Reviews Immunology · doi:10.1038/nri1498 · Cited by 1,024
Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine
Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P., & Ostrand-Rosenberg, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2587 · Cited by 949
Murdoch, C., Giannoudis, A., & Lewis, C. E. (2004) · Blood · doi:10.1182/blood-2004-03-1109 · Cited by 915
Hydroxylation of HIF-1: Oxygen Sensing at the Molecular Level
Semenza, G. L. (2004) · Physiology · doi:10.1152/physiol.00001.2004 · Cited by 905
Mazzone, M., Dettori, D., Leite de Oliveira, R., Loges, S., Schmidt, T., Jonckx, B., Tian, Y.-M., Lanahan, A. A., Pollard, P., Ruiz de Almodovar, C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.01.020 · Cited by 812
HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation
Yu, F., White, S. B., Zhao, Q., & Lee, F. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181341498 · Cited by 796
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Targeting renal cell carcinoma with a HIF-2 antagonist
Chen, W., Hill, H., Christie, A., Kim, M. S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016) · Nature · doi:10.1038/nature19796 · Cited by 709
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen
Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S., & Goldrath, A. W. (2013) · Nature Immunology · doi:10.1038/ni.2714 · Cited by 660
Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1439 · Cited by 652
Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S., Van Ginderachter, J. A., Tamagnone, L., & Mazzone, M. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.007 · Cited by 629
Finlay, D. K., Rosenzweig, E., Sinclair, L. V., Feijoo-Carnero, C., Hukelmann, J. L., Rolf, J., Panteleyev, A. A., Okkenhaug, K., & Cantrell, D. A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112607 · Cited by 596
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti, J., Loges, S., Dimmeler, S., & Carmeliet, P. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70212 · Cited by 591
Graham, K., & Unger, E. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s140462 · Cited by 584
Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202366109 · Cited by 560
The impact of hypoxia on tumor-associated macrophages
Henze, A.-T., & Mazzone, M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84427 · Cited by 546
Huang, H., Wang, Z., Zhang, Y., Pradhan, R. N., Ganguly, D., Chandra, R., Murimwa, G., Wright, S., Gu, X., Maddipati, R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.011 · Cited by 542
Self-citationTang, N., Wang, L., Esko, J., Giordano, F. J., Huang, Y., Gerber, H.-P., Ferrara, N., & Johnson, R. S. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.026 · Cited by 540
A peek into cancer-associated fibroblasts: origins, functions and translational impact
LeBleu, V. S., & Kalluri, R. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.029447 · Cited by 537
The hypoxic tumor microenvironment: A driving force for breast cancer progression
Semenza, G. L. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.036 · Cited by 535
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
Palazon, A., Tyrakis, P. A., Macias, D., Veliça, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.003 · Cited by 521
Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
Scharping, N. E., Menk, A. V., Whetstone, R. D., Zeng, X., & Delgoffe, G. M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0103 · Cited by 520
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Hughes, R., Qian, B.-Z., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O. C., Tazzyman, S., Danson, S., Addison, C., Clemons, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3587 · Cited by 518
Land, S. C., & Tee, A. R. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611782200 · Cited by 507
Activation of fibroblasts in cancer stroma
Räsänen, K., & Vaheri, A. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.032 · Cited by 499
Distinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo
Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.617 · Cited by 468
Pan, P.-Y., Ma, G., Weber, K. J., Ozao-Choy, J., Wang, G., Yin, B., Divino, C. M., & Chen, S.-H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1882 · Cited by 467
Imtiyaz, H. Z., Williams, E. P., Hickey, M. M., Patel, S. A., Durham, A. C., Yuan, L.-J., Hammond, R., Gimotty, P. A., Keith, B., & Simon, M. C. (2010) · Journal of Clinical Investigation · doi:10.1172/jci39506 · Cited by 461
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
Wong, C. C.-L., Gilkes, D. M., Zhang, H., Chen, J., Wei, H., Chaturvedi, P., Fraley, S. I., Wong, C.-M., Khoo, U.-S., Ng, I. O.-L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113483108 · Cited by 437
Biswas, S. K., Sica, A., & Lewis, C. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2011 · Cited by 435
The ever-expanding role of HIF in tumour and stromal biology
LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 430
Caldwell, C. C., Kojima, H., Lukashev, D., Armstrong, J., Farber, M., Apasov, S. G., & Sitkovsky, M. V. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.11.6140 · Cited by 420
Jantsch, J., Chakravortty, D., Turza, N., Prechtel, A. T., Buchholz, B., Gerlach, R. G., Volke, M., Gläsner, J., Warnecke, C., Wiesener, M. S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4697 · Cited by 414
Jayaprakash, P., Ai, M., Liu, A., Budhani, P., Bartkowiak, T., Sheng, J., Ager, C., Nicholas, C., Jaiswal, A. R., Sun, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96268 · Cited by 399
Albini, A., Bruno, A., Noonan, D. M., & Mortara, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00527 · Cited by 392
Allavena, P., & Mantovani, A. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 384
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Kim, H.-J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0216 · Cited by 380
Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer
Saatci, O., Kaymak, A., Raza, U., Ersan, P. G., Akbulut, O., Banister, C. E., Sikirzhytski, V., Tokat, U. M., Aykut, G., Ansari, S. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16199-4 · Cited by 368
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer
Chouaib, S., Noman, M. Z., Kosmatopoulos, K., & Curran, M. A. (2017) · Oncogene · doi:10.1038/onc.2016.225 · Cited by 365
The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy
Albadari, N., Deng, S., & Li, W. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1613370 · Cited by 351
Tatsumi, T., Kierstead, L. S., Ranieri, E., Gesualdo, L., Schena, F. P., Finke, J. H., Bukowski, R. M., Mueller-Berghaus, J., Kirkwood, J. M., Kwok, W. W., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012142 · Cited by 314
HIF Inhibitors: Status of Current Clinical Development
Fallah, J., & Rini, B. I. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0752-z · Cited by 308
Ochi, A., Nguyen, A. H., Bedrosian, A. S., Mushlin, H. M., Zarbakhsh, S., Barilla, R., Zambirinis, C. P., Fallon, N. C., Rehman, A., Pylayeva-Gupta, Y., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111706 · Cited by 304
Becker, L. M., O’Connell, J. T., Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H., McGow, A. K., Asara, J. M., Lovisa, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107701 · Cited by 291
miRNAs regulate the HIF switch during hypoxia: a novel therapeutic target
Serocki, M., Bartoszewska, S., Janaszak-Jasiecka, A., Ochocka, R. J., Collawn, J. F., & Bartoszewski, R. (2018) · Angiogenesis · doi:10.1007/s10456-018-9600-2 · Cited by 288
Hypoxia-Induced Gene Expression in Human Macrophages
Burke, B., Giannoudis, A., Corke, K. P., Gill, D., Wells, M., Ziegler-Heitbrock, L., & Lewis, C. E. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63483-9 · Cited by 286
Ye, L.-Y., Chen, W., Bai, X.-L., Xu, X.-Y., Zhang, Q., Xia, X.-F., Sun, X., Li, G.-G., Hu, Q.-D., Fu, Q.-H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0977 · Cited by 275
Myllyharju, J. (2008) · Annals of Medicine · doi:10.1080/07853890801986594 · Cited by 267
Hypoxia controls CD4+CD25+ regulatory T‐cell homeostasis via hypoxia‐inducible factor‐1α
Ben‐Shoshan, J., Maysel‐Auslender, S., Mor, A., Keren, G., & George, J. (2008) · European Journal of Immunology · doi:10.1002/eji.200838318 · Cited by 260
Rahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258
Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells
Mattes, J., Hulett, M., Xie, W., Hogan, S., Rothenberg, M. E., Foster, P., & Parish, C. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021683 · Cited by 256
Skuli, N., Liu, L., Runge, A., Wang, T., Yuan, L., Patel, S., Iruela-Arispe, L., Simon, M. C., & Keith, B. (2009) · Blood · doi:10.1182/blood-2008-12-193581 · Cited by 255
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma
Najjar, Y. G., Menk, A. V., Sander, C., Rao, U., Karunamurthy, A., Bhatia, R., Zhai, S., Kirkwood, J. M., & Delgoffe, G. M. (2019) · JCI Insight · doi:10.1172/jci.insight.124989 · Cited by 233
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine
Hunter, F. W., Wouters, B. G., & Wilson, W. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.79 · Cited by 228
Deng, J., Li, J., Sarde, A., Lines, J. L., Lee, Y.-C., Qian, D. C., Pechenick, D. A., Manivanh, R., Le Mercier, I., Lowrey, C. H., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0507 · Cited by 224
Lu, J., Li, Z., Zink, J. I., & Tamanoi, F. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.06.002 · Cited by 224
Preclinical Efficacy of the Camptothecin-Polymer Conjugate IT-101 in Multiple Cancer Models
Schluep, T., Hwang, J., Cheng, J., Heidel, J. D., Bartlett, D. W., Hollister, B., & Davis, M. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1566 · Cited by 222
Chen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., Hiddingh, L., Roberge, S., Koppel, C., Lauwers, G. Y., et al. (2014) · Hepatology · doi:10.1002/hep.26790 · Cited by 211
Lukashev, D., Klebanov, B., Kojima, H., Grinberg, A., Ohta, A., Berenfeld, L., Wenger, R. H., Ohta, A., & Sitkovsky, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.4962 · Cited by 208
Lee, J. H., Elly, C., Park, Y., & Liu, Y.-C. (2015) · Immunity · doi:10.1016/j.immuni.2015.05.016 · Cited by 203
Endothelial HIF-2α regulates murine pathological angiogenesis and revascularization processes
Skuli, N., Majmundar, A. J., Krock, B. L., Mesquita, R. C., Mathew, L. K., Quinn, Z. L., Runge, A., Liu, L., Kim, M. N., Liang, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57322 · Cited by 200
Bartoszewski, R., Moszyńska, A., Serocki, M., Cabaj, A., Polten, A., Ochocka, R., Dell'Italia, L., Bartoszewska, S., Króliczewski, J., Dąbrowski, M., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802650rr · Cited by 199
Tan, J. K. H., & O'Neill, H. C. (2005) · Journal of Leukocyte Biology · doi:10.1189/jlb.1104664 · Cited by 197
Westendorf, A. M., Skibbe, K., Adamczyk, A., Buer, J., Geffers, R., Hansen, W., Pastille, E., & Jendrossek, V. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000464429 · Cited by 190
Palazón, A., Martínez-Forero, I., Teijeira, A., Morales-Kastresana, A., Alfaro, C., Sanmamed, M. F., Perez-Gracia, J. L., Peñuelas, I., Hervás-Stubbs, S., Rouzaut, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0314 · Cited by 187
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 176
Thiel, M., Caldwell, C. C., Kreth, S., Kuboki, S., Chen, P., Smith, P., Ohta, A., Lentsch, A. B., Lukashev, D., & Sitkovsky, M. V. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000853 · Cited by 175
Guo, X., Xue, H., Shao, Q., Wang, J., Guo, X., Chen, X., Zhang, J., Xu, S., Li, T., Zhang, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11825 · Cited by 170
Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success
Branco-Price, C., Zhang, N., Schnelle, M., Evans, C., Katschinski, D. M., Liao, D., Ellies, L., & Johnson, R. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.017 · Cited by 168
Werno, C., Menrad, H., Weigert, A., Dehne, N., Goerdt, S., Schledzewski, K., Kzhyshkowska, J., & Brune, B. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq088 · Cited by 167
Gropper, Y., Feferman, T., Shalit, T., Salame, T.-M., Porat, Z., & Shakhar, G. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.071 · Cited by 166
HIF‐prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism
Haase, V. H. (2017) · Hemodialysis International · doi:10.1111/hdi.12567 · Cited by 159
Nakamura, H., Makino, Y., Okamoto, K., Poellinger, L., Ohnuma, K., Morimoto, C., & Tanaka, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7592 · Cited by 158
Hypoxia and loss of PHD2 inactivate stromal fibroblasts to decrease tumour stiffness and metastasis
Madsen, C. D., Pedersen, J. T., Venning, F. A., Singh, L. B., Moeendarbary, E., Charras, G., Cox, T. R., Sahai, E., & Erler, J. T. (2015) · The EMBO Reports · doi:10.15252/embr.201540107 · Cited by 157
White, J. R., Harris, R. A., Lee, S. R., Craigon, M., Binley, K., Price, T., Beard, G. L., Mundy, C. R., & Naylor, S. (2003) · Genomics · doi:10.1016/s0888-7543(03)00215-5 · Cited by 154
Eliasof, S., Lazarus, D., Peters, C. G., Case, R. I., Cole, R. O., Hwang, J., Schluep, T., Chao, J., Lin, J., Yen, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1309566110 · Cited by 144
Noman, M. Z., Janji, B., Hu, S., Wu, J. C., Martelli, F., Bronte, V., & Chouaib, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0405 · Cited by 143
Amelio, I., Mancini, M., Petrova, V., Cairns, R. A., Vikhreva, P., Nicolai, S., Marini, A., Antonov, A. A., Le Quesne, J., Baena Acevedo, J. D., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808314115 · Cited by 139
Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy
Baran, N., & Konopleva, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0895 · Cited by 138
Bellone, G., Carbone, A., Smirne, C., Scirelli, T., Buffolino, A., Novarino, A., Stacchini, A., Bertetto, O., Palestro, G., Sorio, C., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3448 · Cited by 136
HIF-2α is indispensable for regulatory T cell function
Hsu, T.-S., Lin, Y.-L., Wang, Y.-A., Mo, S.-T., Chi, P.-Y., Lai, A. C.-Y., Pan, H.-Y., Chang, Y.-J., & Lai, M.-Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18731-y · Cited by 126
Bosco, M. C., Pierobon, D., Blengio, F., Raggi, F., Vanni, C., Gattorno, M., Eva, A., Novelli, F., Cappello, P., Giovarelli, M., et al. (2011) · Blood · doi:10.1182/blood-2010-06-292136 · Cited by 125
Kugeratski, F. G., Atkinson, S. J., Neilson, L. J., Lilla, S., Knight, J. R. P., Serneels, J., Juin, A., Ismail, S., Bryant, D. M., Markert, E. K., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aan8247 · Cited by 125
Liu, Y.-N., Yang, J.-F., Huang, D.-J., Ni, H.-H., Zhang, C.-X., Zhang, L., He, J., Gu, J.-M., Chen, H.-X., Mai, H.-Q., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01906 · Cited by 124
Peeters, S. G. J. A., Zegers, C. M. L., Biemans, R., Lieuwes, N. G., van Stiphout, R. G. P. M., Yaromina, A., Sun, J. D., Hart, C. P., Windhorst, A. D., van Elmpt, W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0018 · Cited by 120
Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113
Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
de Almeida, P. E., Mak, J., Hernandez, G., Jesudason, R., Hérault, A., Javinal, V., Borneo, J., Kim, J. M., & Walsh, K. B. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0360 · Cited by 113
Spiegelberg, L., Houben, R., Niemans, R., de Ruysscher, D., Yaromina, A., Theys, J., Guise, C. P., Smaill, J. B., Patterson, A. V., Lambin, P., et al. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.01.005 · Cited by 111
Darce, J., Rudra, D., Li, L., Nishio, J., Cipolletta, D., Rudensky, A. Y., Mathis, D., & Benoist, C. (2012) · Immunity · doi:10.1016/j.immuni.2012.04.007 · Cited by 109
Influence of hypoxia-inducible factor 1α on dendritic cell differentiation and migration
Köhler, T., Reizis, B., Johnson, R. S., Weighardt, H., & Förster, I. (2012) · European Journal of Immunology · doi:10.1002/eji.201142053 · Cited by 108
Aguilera, K. Y., Rivera, L. B., Hur, H., Carbon, J. G., Toombs, J. E., Goldstein, C. D., Dellinger, M. T., Castrillon, D. H., & Brekken, R. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2800 · Cited by 100
Self-citationSada, M., Ohuchida, K., Horioka, K., Okumura, T., Moriyama, T., Miyasaka, Y., Ohtsuka, T., Mizumoto, K., Oda, Y., & Nakamura, M. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.016 · Cited by 100
Cutting Edge: Hypoxia-Inducible Factor 1 Negatively Regulates Th1 Function
Shehade, H., Acolty, V., Moser, M., & Oldenhove, G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402552 · Cited by 96
Kheshtchin, N., Arab, S., Ajami, M., Mirzaei, R., Ashourpour, M., Mousavi-Niri, N., Khosravianfar, N., Jadidi‐Niaragh, F., Namdar, A., Noorbakhsh, F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1879-5 · Cited by 96
Kutluk Cenik, B., Ostapoff, K. T., Gerber, D. E., & Brekken, R. A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0995 · Cited by 95
Self-citationChiavarina, B., Martinez-Outschoorn, U. E., Whitaker-Menezes, D., Howell, A., Tanowitz, H. B., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2012) · Cell Cycle · doi:10.4161/cc.21643 · Cited by 80
López-Codony, V., & Tavassoli, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101017 · Cited by 77
Naldini, A., Morena, E., Pucci, A., Miglietta, D., Riboldi, E., Sozzani, S., & Carraro, F. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22761 · Cited by 75
Kuchnio, A., Moens, S., Bruning, U., Kuchnio, K., Cruys, B., Thienpont, B., Broux, M., Ungureanu, A. A., Leite de Oliveira, R., Bruyère, F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.010 · Cited by 73
Pham, E., Yin, M., Peters, C. G., Lee, C. R., Brown, D., Xu, P., Man, S., Jayaraman, L., Rohde, E., Chow, A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3435 · Cited by 73
Extracellular matrix genes as hypoxia-inducible targets
Myllyharju, J., & Schipani, E. (2010) · Cell and Tissue Research · doi:10.1007/s00441-009-0841-7 · Cited by 69
Hypoxia-activated nanomedicines for effective cancer therapy
Zhou, M., Xie, Y., Xu, S., Xin, J., Wang, J., Han, T., Ting, R., Zhang, J., & An, F. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112274 · Cited by 60
Filippi, I., Morena, E., Aldinucci, C., Carraro, F., Sozzani, S., & Naldini, A. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24666 · Cited by 58
Hypoxic Signalling in Tumour Stroma
Laitala, A., & Erler, J. T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00189 · Cited by 58
Loss of Fibroblast HIF-1α Accelerates Tumorigenesis
Kim, J.-W., Evans, C., Weidemann, A., Takeda, N., Lee, Y. S., Stockmann, C., Branco-Price, C., Brandberg, F., Leone, G., Ostrowski, M. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0534 · Cited by 57
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives
Shang, B., Cao, Z., & Zhou, Q. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0176-8 · Cited by 57
Pierobon, D., Bosco, M. C., Blengio, F., Raggi, F., Eva, A., Filippi, M., Musso, T., Novelli, F., Cappello, P., Varesio, L., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242709 · Cited by 56
Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., DeNichilo, M., Ingman, W., Atkins, G. J., Findlay, D. M., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.11.020 · Cited by 56
Minnelide, a novel drug for pancreatic and liver cancer
Banerjee, S., & Saluja, A. K. (2015) · Pancreatology · doi:10.1016/j.pan.2015.05.472 · Cited by 56
Muscle cramping in phase i clinical trials of tirapazamine (SR 4233) with and without radiation
Doherty, N., Hancock, S., Kaye, S. B., Coleman, C. N., Shulman, L. N., Marquez, C., Mariscal, C. S., Rampling, R. P., Senan, S., & von Roemeling, R. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90293-3 · Cited by 55
Metformin: A Possible Option in Cancer Chemotherapy
Ugwueze, C. V., Ogamba, O. J., Young, E. E., Onyenekwe, B. M., & Ezeokpo, B. C. (2020) · Analytical Cellular Pathology · doi:10.1155/2020/7180923 · Cited by 54
Seeley, T. W., Sternlicht, M. D., Klaus, S. J., Neff, T. B., & Liu, D. Y. (2017) · Hypoxia · doi:10.2147/hp.s130526 · Cited by 53
Saggar, J. K., & Tannock, I. F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2298 · Cited by 52
Hypoxia and its therapeutic possibilities in paediatric cancers
Bernauer, C., Man, Y. K. S., Chisholm, J., Lepicard, E. Y., Robinson, S. P., & SHIPLEY, J. M. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01107-w · Cited by 52
Brenner, A. J., Floyd, J., Fichtel, L., Michalek, J. E., Kanakia, K. P., Huang, S., Reardon, D. A., Wen, P. Y., & Lee, E. Q. (2021) · Scientific Reports · doi:10.1038/s41598-021-81841-0 · Cited by 49
Hypoxia-adaptive pathways: A pharmacological target in fibrotic disease?
Strowitzki, M. J., Ritter, A. S., Kimmer, G., & Schneider, M. A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104364 · Cited by 48
Lohse, I., Rasowski, J., Cao, P. M., Pintilie, M., Do, T., Tsao, M., Hill, R. P., & Hedley, D. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9654 · Cited by 48
Lin, C., Lin, Y., Luh, F., Yen, Y., & Chen, R. (2016) · Oncotarget · doi:10.18632/oncotarget.9878 · Cited by 46
The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer
Huang, H., & Brekken, R. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3751 · Cited by 44
Self-citationGetting a grip on adhesion: Cadherin switching and collagen signaling
Huang, H., Wright, S., Zhang, J., & Brekken, R. A. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.04.002 · Cited by 44
Self-citationRationale for hypoxia assessment and amelioration for precision therapy and immunotherapy studies
Dewhirst, M. W., Mowery, Y. M., Mitchell, J. B., Cherukuri, M. K., & Secomb, T. W. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126044 · Cited by 41
Huang, H., Wang, Z., Zhang, Y., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.04.429827 · Cited by 41
Self-citationHypoxia-inducible factor 1 alpha limits dendritic cell stimulation of CD8 T cell immunity
Tran, C. W., Gold, M. J., Garcia-Batres, C. R., Tai, K., Elford, A. R., Himmel, M. E., Elia, A., & Ohashi, P. S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0244366 · Cited by 40
Ogino, T., Onishi, H., Suzuki, H. Y., Morisaki, T., Tanaka, M., & Katano, M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1112-5 · Cited by 38
Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro
Xie, C., Gao, X., Sun, D., Zhang, Y.-B., Krausz, K. W., Qin, X., & Gonzalez, F. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079723 · Cited by 37
Self-citationQian, X., Zhang, Q., Shao, N., Shan, Z., Cheang, T., Zhang, Z., Su, Q., Wang, S., & Lin, Y. (2019) · Europe PMC (PubMed Central) · Cited by 36
Strowd, R., Ellingson, B., Raymond, C., Yao, J., Wen, P. Y., Ahluwalia, M., Piotrowski, A., Desai, A., Clarke, J. L., Lieberman, F. S., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04456-7 · Cited by 36
Zhang, L., Marrano, P. M., Wu, B. H., Kumar, S., Thorner, P. S., & Baruchel, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1853 · Cited by 35
Goggins, E. S., Kakkad, S. M., Mironchik, Y., Jacob, D., Wildes, F. B., Krishnamachary, B., & Bhujwalla, Z. M. (2017) · Neoplasia · doi:10.1016/j.neo.2017.11.010 · Cited by 34
Increased expression of surface CD44 in hypoxia-DCs skews helper T cells toward a Th2 polarization
Yang, M., Liu, Y., Ren, G., Shao, Q., Gao, W., Sun, J., Wang, H., Ji, C., Li, X., Zhang, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep13674 · Cited by 31
Self-citationYoon, C., Lee, H.-J., Park, D. J., Lee, Y., Tap, W. D., Eisinger‐Mathason, T. S. K., Hart, C. P., Choy, E., Simon, M. C., & Yoon, S. S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.186 · Cited by 31
Pharmacological HIF-inhibition attenuates postoperative adhesion formation
Strowitzki, M. J., Ritter, A. S., Radhakrishnan, P., Harnoss, J. M., Opitz, V. M., Biller, M., Wehrmann, J., Keppler, U., Scheer, J., Wallwiener, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13638-z · Cited by 30
Fjeldbo, C. S., Hompland, T., Hillestad, T., Aarnes, E., Günther, C., Kristensen, G. B., Malinen, E., & Lyng, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102841 · Cited by 28
Inhibition of HIF-prolyl hydroxylases improves healing of intestinal anastomoses
Strowitzki, M. J., Kimmer, G., Wehrmann, J., Ritter, A. S., Radhakrishnan, P., Opitz, V. M., Tuffs, C., Biller, M., Kugler, J., Keppler, U., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.139191 · Cited by 26
Schmidt, K. T., Chau, C. H., Strope, J. D., Huitema, A. D. R., Sissung, T. M., Price, D. K., & Figg, W. D. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0228 · Cited by 24
Kumar, S., Sun, J. D., Zhang, L., Mokhtari, R. B., Wu, B. H., Meng, F., Liu, Q., Bhupathi, D., Wang, Y., Yeger, H., et al. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.05.004 · Cited by 19
Hypoxia-Induced Metabolomic Alterations in Pancreatic Cancer Cells
Gunda, V., Kumar, S., Dasgupta, A., & Singh, P. K. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7665-2_9 · Cited by 17
Meaney, C., Rhebergen, S., & Kohandel, M. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007926 · Cited by 17
Strowd, R. E., Ellingson, B. M., Wen, P. Y., Ahluwalia, M. S., Piotrowski, A. F., Desai, A. S., Clarke, J. L., Lieberman, F. S., Desideri, S., Nabors, L. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2027 · Cited by 16
Bohan, P. M. K., Chick, R. C., O’Shea, A. E., Vreeland, T. J., Hickerson, A. T., Cindass, J. L., Ensley, D. C., Hale, D. F., Clifton, G. T., Sohn, V. Y., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0383 · Cited by 15
Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma
Liu, S., Tetzlaff, M. T., Wang, T., Chen, X., Yang, R., Kumar, S. M., Vultur, A., Li, P., Martin, J. S., Herlyn, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22944 · Cited by 14
Phase II clinical trial evaluating CRLX101 in recurrent ovarian, tubal, and peritoneal cancer.
Krasner, C. N., Birrer, M. J., Berlin, S. T., Horowitz, N. S., Buss, M. K., Eliasof, S. D., Garmey, E. G., Hennessy, M. G., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5581 · Cited by 9
Huang, H., Wang, Z., Zhang, Y., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3790948 · Cited by 5
Self-citation
Cited by
Zi, Y., Yang, K., He, J., Wu, Z., Liu, J., & Zhang, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114449 · Cited by 268
Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment
Kim, I., Choi, S., Yoo, S., Lee, M., & Kim, I. (2022) · Cancers · doi:10.3390/cancers14143321 · Cited by 118
“CAFs are prominent component of the tumor microenvironment and are regulated under hypoxia by both HIF dependent and independent mechanisms [26,38].”
BackgroundThe impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 106
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Furthermore, hypoxia promotes self-renewal by activation of Wnt and Notch signaling pathways and embryonic stem cell transcription factors, and it modulates differentiation of tumor cells and tumor-associated stromal cells [86–88].”
Tumour hypoxia in driving genomic instability and tumour evolution
Suvac, A., Ashton, J., & Bristow, R. G. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-024-00781-9 · Cited by 139
“The tumour microenvironment consists of multiple cell types (immune cells, stromal cells and endothelial cells) and may vary within normoxic versus hypoxic compartments 286 .”
Metadata
- Authors
- Zhang, Y., Coleman, M., & Brekken, R. A.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Brekken, Rolf A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-06-20
- Volume
- 13
- Issue
- 12
- Pages
- 3070
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC8234221
- OpenAlex
- W3174016551
- Cited by
- 39
- References
- 189
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 5 · 2023: 5 · 2022: 10 · 2021: 3
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (U54 CA210181 (Project 2); R01 CA243577)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor hypoxia, hypoxia signaling, hypoxia-inducible factor, tumor stroma, tumor microenvironment, tumor vasculature, extracellular matrix, tumor immune microenvironment, immunosuppression, treatment resistance, hypoxia-targeted therapy, tumor progression, metastasis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.